PMID- 16842528
OWN - NLM
STAT- MEDLINE
DCOM- 20070104
LR  - 20131121
IS  - 0902-0063 (Print)
IS  - 0902-0063 (Linking)
VI  - 20
IP  - 4
DP  - 2006 Jul-Aug
TI  - Comparative outcomes of reduced intensity and myeloablative allogeneic 
      hematopoietic stem cell transplantation in patients under 50 with hematologic 
      malignancies.
PG  - 496-503
AB  - We have conducted a direct comparison of the outcomes of reduced intensity and 
      myeloablative conditioning in younger adults with hematological malignancies<50 
      yr. One hundred and five patients received transplants from human leukocyte 
      antigen (HLA)-matched donors, via either reduced intensity (n=35) or 
      myeloablative conditioning (n=70). The median ages of the reduced intensity and 
      myeloablative groups were 36 and 33 yr (p=0.014). Neutrophil engraftment (i.e. 
      time to absolute neutrophil count>0.5x10(9)/L) occurred more rapidly in the 
      reduced intensity group (median: 10 d; range: 0-21 d) than in the myeloablative 
      group (median: 18 d; range: 11-38 d; p<0.0001). The incidence of grades 2-4 acute 
      graft-vs.-host disease were similar between the reduced intensity and 
      myeloablative groups, at 17% vs. 24% respectively (p=0.40). The cumulative 
      incidence of day 100 non-relapse mortality was 18% in the reduced intensity 
      group, and 21% in the myeloablative group (p=0.88). The overall two-yr survival 
      rates were 43% in the reduced intensity group, and 35% in the myeloablative group 
      (p=0.72). In conclusion, reduced intensity transplantation yielded outcomes 
      comparable with those of myeloablative transplantation in patients under 50 with 
      hematological malignancies.
FAU - Kim, Inho
AU  - Kim I
AD  - Department of Internal Medicine, Seoul National University, College of Medicine, 
      Seoul, Korea.
FAU - Yoon, Sung Soo
AU  - Yoon SS
FAU - Lee, Kyung-Hun
AU  - Lee KH
FAU - Keam, Bhumsuk
AU  - Keam B
FAU - Kim, Tae Min
AU  - Kim TM
FAU - Kim, Jin-Soo
AU  - Kim JS
FAU - Kim, Hoon-Gu
AU  - Kim HG
FAU - Oh, Myoung-Don
AU  - Oh MD
FAU - Han, Kyou-Sup
AU  - Han KS
FAU - Park, Myoung Hee
AU  - Park MH
FAU - Park, Seonyang
AU  - Park S
FAU - Kim, Byoung Kook
AU  - Kim BK
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Female
MH  - Graft vs Host Disease
MH  - Hematologic Neoplasms/mortality/*therapy
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Melphalan/administration & dosage
MH  - Middle Aged
MH  - Survival Analysis
MH  - Transplantation Conditioning
MH  - Transplantation, Homologous/*physiology
MH  - Treatment Outcome
EDAT- 2006/07/18 09:00
MHDA- 2007/01/05 09:00
CRDT- 2006/07/18 09:00
PHST- 2006/07/18 09:00 [pubmed]
PHST- 2007/01/05 09:00 [medline]
PHST- 2006/07/18 09:00 [entrez]
AID - CTR512 [pii]
AID - 10.1111/j.1399-0012.2006.00512.x [doi]
PST - ppublish
SO  - Clin Transplant. 2006 Jul-Aug;20(4):496-503. doi: 
      10.1111/j.1399-0012.2006.00512.x.